Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Immunovia AB ( (SE:IMMNOV) ) is now available.
Immunovia AB has secured a licensing agreement with Proteomedix to acquire assets and intellectual property that will significantly reduce the cost of its PancreaSure pancreatic cancer test. This agreement allows Immunovia to cut reagent costs by 50% and gain control over its supply chain, with upfront payments to Proteomedix and a royalty on future sales. The move is expected to streamline operations and enhance cost management, funded by proceeds from an upcoming rights issue.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes tests to detect proteins and blood-based antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to make these tests available to high-risk individuals. The USA is the largest market for pancreatic cancer detection, with millions at high risk who could benefit from annual surveillance testing. Immunovia’s shares are listed on Nasdaq Stockholm.
YTD Price Performance: -0.92%
Average Trading Volume: 10,496,105
Technical Sentiment Signal: Sell
Current Market Cap: SEK165.6M
Learn more about IMMNOV stock on TipRanks’ Stock Analysis page.